{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:51:51Z","timestamp":1788292311084,"version":"build-2803163510"},"reference-count":61,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immunotherapy has become standard of care in the treatment of diffuse large B-cell lymphoma (DLBCL). Changes in immunophenotypes observed at first diagnosis predict therapy outcome but little is known about the resolution of these alterations in remission. Comprehensive characterization of immune changes from fresh, peripheral whole blood revealed a functionally relevant increase of myeloid-derived suppressor cells, reduced na\u00efve T cells, and an increase of activated and terminally differentiated T cells before treatment, which aggravated after therapy. Suggesting causal relation, injection of lymphoma in mice induced similar changes in the murine T cells. Distinct immune imprints were found in those who have survived breast cancer and acute myeloid leukemia. Identified alterations persisted beyond 5 years of ongoing complete remission and correlated with increased proinflammatory markers such as interleukin-6, \u03b22-microglobulin, or soluble CD14 in DLBCL. The chronic inflammation was associated with functionally blunted T-cell immunity against severe acute respiratory syndrome coronavirus 2\u2013specific peptides, and reduced responses correlated with reduced na\u00efve T cells. Persisting inflammation was confirmed by deep sequencing and by cytokine profiles, together pointing toward a compensatory activation of innate immunity. The persisting, lymphoma-induced immune alterations in remission may explain long-term complications, have implications for vaccine strategies, and are likely relevant for immunotherapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024027877","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:07:56Z","timestamp":1747152476000},"page":"1300-1313","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6219-6608","authenticated-orcid":false,"given":"Richard J.","family":"Pelzl","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benintende","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0911-2204","authenticated-orcid":false,"given":"Franziska","family":"Gsottberger","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Scholz","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2408-1138","authenticated-orcid":false,"given":"Matthias","family":"Ruebner","sequence":"additional","affiliation":[{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"4Comprehensive Cancer Center Erlangen, European Metropolitan Region N\u00fcrnberg, Erlangen, Germany"},{"name":"5Comprehensive Cancer Center Alliance, W\u00fcrzburg, Erlangen, Regensburg, Augsburg, Erlangen, Germany"},{"name":"6Department of Gynecology and Obstetrics, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yao","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-5437","authenticated-orcid":false,"given":"Kerstin","family":"Wendland","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"7Department of Medicine III, Hematology\/Oncology, Ludwig Maximilian University Hospital, Ludwig Maximilian University of Munich, Munich, Germany"},{"name":"8Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Altmann","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2328-5251","authenticated-orcid":false,"given":"Srdjan","family":"Petkovic","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4650-5357","authenticated-orcid":false,"given":"Lisa","family":"Mellenthin","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"K\u00fcbel","sequence":"additional","affiliation":[{"name":"10Department of Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-8393","authenticated-orcid":false,"given":"Moritz","family":"Schmiedeberg","sequence":"additional","affiliation":[{"name":"10Department of Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Klein","sequence":"additional","affiliation":[{"name":"10Department of Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-6195","authenticated-orcid":false,"given":"Agnese","family":"Petrera","sequence":"additional","affiliation":[{"name":"11Metabolomics and Proteomics Core, Helmholtz Zentrum M\u00fcnchen, German Research Center for Environmental Health, Neuherberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Baur","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1876-2196","authenticated-orcid":false,"given":"Sophie","family":"Eckstein","sequence":"additional","affiliation":[{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"4Comprehensive Cancer Center Erlangen, European Metropolitan Region N\u00fcrnberg, Erlangen, Germany"},{"name":"5Comprehensive Cancer Center Alliance, W\u00fcrzburg, Erlangen, Regensburg, Augsburg, Erlangen, Germany"},{"name":"6Department of Gynecology and Obstetrics, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Hoepffner-Grundy","sequence":"additional","affiliation":[{"name":"12Joint Practice Drs. Hoepffner-Grundy and Kasanmascheff, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3791-0548","authenticated-orcid":false,"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"4Comprehensive Cancer Center Erlangen, European Metropolitan Region N\u00fcrnberg, Erlangen, Germany"},{"name":"13Laboratory for Translational Research, Gene Center, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-1493","authenticated-orcid":false,"given":"Hanna","family":"Huebner","sequence":"additional","affiliation":[{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"4Comprehensive Cancer Center Erlangen, European Metropolitan Region N\u00fcrnberg, Erlangen, Germany"},{"name":"5Comprehensive Cancer Center Alliance, W\u00fcrzburg, Erlangen, Regensburg, Augsburg, Erlangen, Germany"},{"name":"6Department of Gynecology and Obstetrics, Universit\u00e4tsklinikum Erlangen, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"14Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0685-4483","authenticated-orcid":false,"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-1396","authenticated-orcid":false,"given":"Luca","family":"Laurenti","sequence":"additional","affiliation":[{"name":"15Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1198-6632","authenticated-orcid":false,"given":"Frederik","family":"Graw","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-3048","authenticated-orcid":false,"given":"Simon","family":"V\u00f6lkl","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystelle","family":"Nganou-Makamdop","sequence":"additional","affiliation":[{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"10Department of Clinical and Molecular Virology, Friedrich-Alexander-University Erlangen, Erlangen, Germany"},{"name":"14Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-5839","authenticated-orcid":false,"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"},{"name":"2Bavarian Cancer Research Center, Erlangen and Munich, Germany"},{"name":"3Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universit\u00e4t Erlangen and University Hospital Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025091111215747600_bib1","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2025091111215747600_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2025091111215747600_bib3","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"suppl 16","key":"2025091111215747600_bib4","doi-asserted-by":"crossref","first-page":"TPS7592","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7592","article-title":"Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2","volume":"41","author":"Sehn","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"2025091111215747600_bib5","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2023.41.16_suppl.7549","article-title":"Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): results from a phase Ib study","volume":"41","author":"Dickinson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025091111215747600_bib6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"2025091111215747600_bib7","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.19.01937","article-title":"Impaired immune health in survivors of diffuse large B-cell lymphoma","volume":"38","author":"Shree","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025091111215747600_bib8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1001\/jama.2020.23130","article-title":"Association of first primary cancer with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States","volume":"324","author":"Sung","year":"2020","journal-title":"JAMA"},{"issue":"19","key":"2025091111215747600_bib9","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.30164","article-title":"Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008","volume":"122","author":"Donin","year":"2016","journal-title":"Cancer"},{"issue":"33","key":"2025091111215747600_bib10","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025091111215747600_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","article-title":"Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels","volume":"22","author":"Roider","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"5","key":"2025091111215747600_bib12","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2025091111215747600_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"2025091111215747600_bib14","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025091111215747600_bib15","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","article-title":"Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"50","author":"Winkelmann","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2025091111215747600_bib16","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"2025091111215747600_bib17","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025091111215747600_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2019.243626","article-title":"Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma","volume":"106","author":"Autio","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"2025091111215747600_bib19","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2025091111215747600_bib20","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/- monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2025091111215747600_bib21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2025091111215747600_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2025091111215747600_bib23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/emmm.201202382","article-title":"Resolution of inflammation: an integrated view","volume":"5","author":"Ortega-G\u00f3mez","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"6","key":"2025091111215747600_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.medj.2024.03.007","article-title":"Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas","volume":"5","author":"Arffman","year":"2024","journal-title":"Med"},{"key":"2025091111215747600_bib25","doi-asserted-by":"crossref","first-page":"180.e5","DOI":"10.1016\/j.medj.2020.10.006","article-title":"A systemic protein deviation score linked to PD-1+ CD8+ T cell expansion that predicts overall survival in diffuse large B cell lymphoma","volume":"2","author":"Ask","year":"2021","journal-title":"Med"},{"issue":"38","key":"2025091111215747600_bib26","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"4","key":"2025091111215747600_bib27","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/HS9.0000000000000858","article-title":"Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL","volume":"7","author":"Rejeski","year":"2023","journal-title":"HemaSphere"},{"issue":"18","key":"2025091111215747600_bib28","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1093\/bioinformatics\/btv309","article-title":"IMSEQ--a fast and error aware approach to immunogenetic sequence analysis","volume":"31","author":"Kuchenbecker","year":"2015","journal-title":"Bioinformatics"},{"issue":"19","key":"2025091111215747600_bib29","doi-asserted-by":"crossref","first-page":"10433","DOI":"10.3390\/ijms221910433","article-title":"Human CD22-transgenic, primary murine lymphoma challenges immunotherapies in organ-specific tumor microenvironments","volume":"22","author":"Gsottberger","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2025091111215747600_bib30","doi-asserted-by":"crossref","first-page":"3899.e16","DOI":"10.1016\/j.cell.2021.05.023","article-title":"Translocated microbiome composition determines immunological outcome in treated HIV infection","volume":"184","author":"Nganou-Makamdop","year":"2021","journal-title":"Cell"},{"issue":"12","key":"2025091111215747600_bib31","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"2025091111215747600_bib32","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41467-018-05800-6","article-title":"Resolution of chronic inflammatory disease: universal and tissue-specific concepts","volume":"9","author":"Schett","year":"2018","journal-title":"Nat Commun"},{"issue":"310","key":"2025091111215747600_bib33","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci Transl Med"},{"issue":"9","key":"2025091111215747600_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2025091111215747600_bib35","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00262-017-2026-7","article-title":"Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy","volume":"66","author":"Battella","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2025091111215747600_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3892\/ol.2024.14370","article-title":"Assessment and prognostic significance of a serum cytokine panel in diffuse large B-cell lymphoma","volume":"27","author":"Xie","year":"2024","journal-title":"Oncol Lett"},{"issue":"4","key":"2025091111215747600_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Naive T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"2025091111215747600_bib38","doi-asserted-by":"crossref","first-page":"13471","DOI":"10.1038\/s41598-019-50029-y","article-title":"Recovery of central memory and naive peripheral T cells in Follicular Lymphoma patients receiving rituximab-chemotherapy based regimen","volume":"9","author":"Milcent","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"2025091111215747600_bib39","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood.V90.9.3662","article-title":"Long-term depletion of naive T cells in patients treated for Hodgkin's disease","volume":"90","author":"Watanabe","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2025091111215747600_bib40","doi-asserted-by":"crossref","first-page":"e794","DOI":"10.1097\/HS9.0000000000000794","article-title":"Immune biomarkers in the peripheral blood and tumor microenvironment of classical Hodgkin lymphoma patients in relation to tumor burden and response to treatment","volume":"6","author":"Mulder","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"2025091111215747600_bib41","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2013-12-546416","article-title":"CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs","volume":"124","author":"Jitschin","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2025091111215747600_bib42","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.immuni.2015.05.013","article-title":"Thymic B cells are licensed to present self antigens for central T cell tolerance Induction","volume":"42","author":"Yamano","year":"2015","journal-title":"Immunity"},{"issue":"6536","key":"2025091111215747600_bib43","doi-asserted-by":"crossref","first-page":"eabc4552","DOI":"10.1126\/science.abc4552","article-title":"The microbiome and human cancer","volume":"371","author":"Sepich-Poore","year":"2021","journal-title":"Science"},{"issue":"3","key":"2025091111215747600_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41591-019-0377-7","article-title":"The microbiome, cancer, and cancer therapy","volume":"25","author":"Helmink","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"2025091111215747600_bib45","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41416-024-02816-2","article-title":"Infections and their prognostic significance before diagnosis of chronic lymphocytic leukemia, non-Hodgkin lymphoma, or multiple myeloma","volume":"131","author":"Packness","year":"2024","journal-title":"Br J Cancer"},{"issue":"6","key":"2025091111215747600_bib46","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000449251","article-title":"Influence of R-CHOP therapy on immune system restoration in patients with B-cell lymphoma","volume":"91","author":"Ito","year":"2016","journal-title":"Oncology"},{"issue":"11","key":"2025091111215747600_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"2025091111215747600_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2025091111215747600_bib49","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/nm.3350","article-title":"Cellular immune correlates of protection against symptomatic pandemic influenza","volume":"19","author":"Sridhar","year":"2013","journal-title":"Nat Med"},{"issue":"9","key":"2025091111215747600_bib50","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.immuni.2021.08.001","article-title":"Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination","volume":"54","author":"Painter","year":"2021","journal-title":"Immunity"},{"issue":"10","key":"2025091111215747600_bib51","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/bloodadvances.2022007806","article-title":"Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR-T cell therapy","volume":"7","author":"Reimann","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2025091111215747600_bib52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ccell.2022.01.010","article-title":"Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients","volume":"40","author":"Sesques","year":"2022","journal-title":"Cancer Cell"},{"issue":"5","key":"2025091111215747600_bib53","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025091111215747600_bib54","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025091111215747600_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2025091111215747600_bib56","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"2025091111215747600_bib57","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"2025091111215747600_bib58","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"2025091111215747600_bib59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2011.02.003","article-title":"IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer","volume":"22","author":"Neurath","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"2025091111215747600_bib60","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","article-title":"The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk","volume":"48","author":"Popa","year":"2007","journal-title":"J Lipid Res"},{"issue":"1","key":"2025091111215747600_bib61","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41467-017-01973-8","article-title":"Meta-analysis of gut microbiome studies identifies disease-specific and shared responses","volume":"8","author":"Duvallet","year":"2017","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/11\/1300\/2411724\/blood_bld-2024-027877-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/11\/1300\/2411724\/blood_bld-2024-027877-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:22:12Z","timestamp":1757604132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/11\/1300\/537244\/Large-B-cell-lymphoma-imprints-a-dysfunctional"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":61,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027877","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9,11]]},"published":{"date-parts":[[2025,9,11]]}}}